You've likely heard a million different warnings about the changes taking place in America's financial system right now... How the White House plans to take the dollar fully digital???

Todd Simpson Biography and Net Worth

CFO of Seagen

Todd brings extensive financial leadership experience, most notably at public biotechnology companies, to Seagen. Leveraging this expertise, he has positioned our finance, investor relations, communications and facilities teams to support the company’s mission and continued growth.

Prior to joining Seagen, Todd was the Vice President of Finance and Administration and Chief Financial Officer at both Targeted Genetics and Aastrom Biosciences (now Vericel Corporation). He also held positions at Integra LifeSciences Corporation and Telios Pharmaceuticals, Inc. Todd began his career at Ernst & Young LLP in the life sciences and technology practices.

Todd holds a B.S. in Accounting and Computer Science from Oregon State University. He is also the Chairman of the Board for Neoleukin Therapeutics, Inc.

What is Todd E. Simpson's net worth?: The estimated net worth of Todd E. Simpson is at least $29.46 million as of August 31st, 2023. Mr. Simpson owns 128,803 shares of Seagen stock worth more than $29,462,398 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Simpson may own. Additionally, Mr. Simpson receives a salary of $1,260,000.00 as CFO at Seagen. Learn More about Todd E. Simpson's net worth.
How old is Todd E. Simpson?: Mr. Simpson is currently 62 years old. There are 4 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who is 67 years old. Learn More on Todd E. Simpson's age.
What is Todd E. Simpson's salary?: As the CFO of Seagen Inc., Mr. Simpson earns $1,260,000.00 per year. There are 2 executives that earn more than Mr. Simpson. The highest earning executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who commands a salary of $2,480,000.00 per year. Learn More on Todd E. Simpson's salary.
How do I contact Todd E. Simpson?: The corporate mailing address for Mr. Simpson and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Todd E. Simpson's contact information.
Has Todd E. Simpson been buying or selling shares of Seagen?: Todd E. Simpson has not been actively trading shares of Seagen during the past quarter. Most recently, Todd E. Simpson sold 2,122 shares of the business's stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $206.97, for a transaction totalling $439,190.34. Following the completion of the sale, the chief financial officer now directly owns 128,803 shares of the company's stock, valued at $26,658,356.91. Learn More on Todd E. Simpson's trading history.
Who are Seagen's active insiders?: Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.
Are insiders buying or selling shares of Seagen?: In the last twelve months, insiders at the biotechnology company sold shares 20 times. They sold a total of 70,520 shares worth more than $14,429,678.66. The most recent insider tranaction occured on November, 10th when CEO David R Epstein sold 10,620 shares worth more than $2,262,166.20. Insiders at Seagen own 25.9% of the company. Learn More about insider trades at Seagen.
Information on this page was last updated on 11/10/2023.

Todd E. Simpson Insider Trading History at Seagen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/31/2023	Sell	2,122	$206.97	$439,190.34	128,803
8/29/2023	Sell	485	$206.00	$99,910.00	130,925
4/10/2023	Sell	55,344	$204.58	$11,322,275.52	118,946
4/6/2023	Sell	243	$205.86	$50,023.98	118,946
3/9/2023	Sell	42,793	$176.61	$7,557,671.73	117,185
2/27/2023	Sell	20,000	$182.53	$3,650,600.00	117,185
2/16/2023	Sell	39,946	$160.00	$6,391,360.00	137,185
8/16/2022	Sell	1,967	$170.22	$334,822.74	141,371
4/20/2022	Sell	567	$144.32	$81,829.44	127,891
11/3/2021	Sell	40,232	$185.00	$7,442,920.00
10/29/2021	Sell	33,564	$180.00	$6,041,520.00
8/31/2021	Sell	3,987	$167.52	$667,902.24
8/16/2021	Sell	533	$154.55	$82,375.15
12/18/2020	Sell	33,669	$200.00	$6,733,800.00
11/5/2020	Sell	7,509	$180.37	$1,354,398.33
8/31/2020	Sell	4,187	$155.69	$651,874.03
8/18/2020	Sell	9,262	$158.17	$1,464,970.54
8/3/2020	Sell	20,000	$165.72	$3,314,400.00
7/1/2020	Sell	11,573	$167.58	$1,939,403.34
5/5/2020	Sell	26,867	$162.94	$4,377,708.98	175,863
9/30/2019	Sell	15,000	$85.00	$1,275,000.00
8/28/2019	Sell	5,909	$73.21	$432,597.89
8/20/2019	Sell	12,500	$80.00	$1,000,000.00
4/5/2019	Sell	12,500	$78.00	$975,000.00
3/4/2019	Sell	10,000	$75.00	$750,000.00
8/27/2018	Sell	5,427	$74.23	$402,846.21
11/1/2017	Sell	39,385	$60.91	$2,398,940.35
9/6/2017	Sell	9,638	$52.00	$501,176.00
8/28/2017	Sell	4,937	$47.89	$236,432.93
8/20/2015	Sell	5,825	$42.02	$244,766.50	179,874
7/12/2013	Sell	92,527	$37.45	$3,465,136.15

Todd E. Simpson Buying and Selling Activity at Seagen

Seagen Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $228.74

$228.74

50 Day Range

MA: $228.74

$228.74

2 Week Range

Now: $228.74

$123.77

$228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Fed launches fourth dollar overhaul

From Stansberry Research | Ad

You've likely heard a million different warnings about the changes taking place in America's financial system right now... How the White House plans to take the dollar fully digital???

Just click here now for the full story.

Todd Simpson Biography and Net Worth

What is Todd E. Simpson's net worth?

How old is Todd E. Simpson?

What is Todd E. Simpson's salary?

How do I contact Todd E. Simpson?

Has Todd E. Simpson been buying or selling shares of Seagen?

Who are Seagen's active insiders?

Are insiders buying or selling shares of Seagen?